Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPBAR1 | Q8TDU6 | 10/20 | 1.00 |
| ▸ | NR1H4 | Q96RI1 | 3/20 | 1.00 |
| ▸ | PDE3A | Q14432 | 2/20 | 1.00 |
| ▸ | SLC10A2 | Q12908 | 2/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 0.80 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.80 |
| ▸ | LMNA | P02545 | 3/20 | 0.80 |
| ▸ | USP2 | O75604 | 2/20 | 0.80 |
| ▸ | MEN1 | O00255 | 1/20 | 0.80 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.80 |
| ▸ | CASP7 | P55210 | 3/20 | 0.77 |
| ▸ | TP53 | P04637 | 2/20 | 0.77 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.77 |
| ▸ | BLM | P54132 | 2/20 | 0.77 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.77 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.77 |
| ▸ | MDM4 | O15151 | 1/20 | 0.77 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.77 |
| ▸ | VDR | P11473 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lagodeoxycholate SCHEMBL12998476 | 1.00 | GPBAR1 (1.00) | GPBAR1NR1H4PDE3ASLC10A2TBXA2R | |
| Lagodeoxycholate SCHEMBL22415902 | 1.00 | GPBAR1 (1.00) | GPBAR1NR1H4PDE3ASLC10A2TBXA2R | |
| Lagodeoxycholate SCHEMBL22415770 | 1.00 | GPBAR1 (1.00) | GPBAR1NR1H4PDE3ASLC10A2TBXA2R | |
| Lagodeoxycholate SCHEMBL24001452 | 1.00 | GPBAR1 (1.00) | GPBAR1NR1H4PDE3ASLC10A2TBXA2R | |
| Lagodeoxycholate SCHEMBL5150699 | 1.00 | GPBAR1 (1.00) | GPBAR1NR1H4PDE3ASLC10A2TBXA2R | |
| Lagodeoxycholate SCHEMBL24032585 | 1.00 | GPBAR1 (1.00) | GPBAR1NR1H4PDE3ASLC10A2TBXA2R | |
| Lagodeoxycholate SCHEMBL24124431 | 1.00 | GPBAR1 (1.00) | GPBAR1NR1H4PDE3ASLC10A2TBXA2R | |
| Lagodeoxycholate SCHEMBL23781732 | 1.00 | GPBAR1 (1.00) | GPBAR1NR1H4PDE3ASLC10A2TBXA2R | |
| Lagodeoxycholate SCHEMBL22778334 | 1.00 | GPBAR1 (1.00) | GPBAR1NR1H4PDE3ASLC10A2TBXA2R | |
| Lagodeoxycholate SCHEMBL12575822 | 1.00 | GPBAR1 (1.00) | GPBAR1NR1H4PDE3ASLC10A2TBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3350313-B1 | DERIVATION OF LIVER ORGANOIDS FROM HUMAN PLURIPOTENT STEM CELLS | AGENCY FOR SCIENCE TECH AND RESEARCH ASTARSTAR (SG) | 2025-11-26 | — | — | EP | claimed |
| US-20230226143-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A COMBINATION OF A GUANYLATE CYCLASE C (GUCY2C) AGONIST AND A SHORT-CHAIN FATTY ACID OR PRODRUG THEREOF | OCVIRK SOREN (DE) | 2023-07-20 | — | — | US | claimed |
| US-20210148893-A1 | METHOD FOR DETERMINING IN VITRO BIOEQUIVALENCE OF A SUCRALFATE SUSPENSION SAMPLE TO A SUCRALFATE SUSPENSION REFERENCE LISTED DRUG (RLD) | CLAYTON PHARMACEUTICALS LLC (US) | 2021-05-20 | — | — | US | claimed |
| EP-3423829-B1 | METHOD FOR DETERMINING IN VITRO BIOEQUIVALENCE OF A SUCRALFATE SUSPENSION SAMPLE TO A SUCRALFATE SUSPENSION REFERENCE LISTED DRUG (RLD) | CLAYTON PHARMACEUTICALS LLC (US) | 2020-10-28 | — | — | EP | claimed |
| CN-110582564-A | derivation of liver organoids from human pluripotent stem cells | 新加坡科技研究局 | 2019-12-17 | — | — | CN | claimed |
| EP-3423829-A1 | METHOD FOR DETERMININGIN VITRO | Clayton Pharmaceuticals LLC (US) | 2019-01-09 | — | — | EP | claimed |
| WO-2018204894-A1 | METHOD FOR DETERMINING IN VITRO BIOEQUIVALENCE OF A SUCRALFATE SUSPENSION SAMPLE TO A SUCRALFATE SUSPENSION REFERENCE LISTED DRUG (RLD) | CLAYTON PHARMACEUTICALS LLC (US) | 2018-11-08 | — | — | WO | claimed |
| US-9989519-B1 | Method for determining in vitro bioequivalence of a sucralfate suspension sample to a sucralfate suspension reference listed drug (RLD) | Clayton Pharmaceuticals, LLC (US) | 2018-06-05 | — | — | US | claimed |
| EP-3350313-B1 | DERIVATION OF LIVER ORGANOIDS FROM HUMAN PLURIPOTENT STEM CELLS | AGENCY FOR SCIENCE TECH AND RESEARCH ASTARSTAR (SG) | 2025-11-26 | — | — | EP | disclosed |
| EP-4378483-A1 | USE OF ST-TYPE LIPID COMPOUNDS IN PREPARATION OF NUCLEIC ACID DELIVERY REAGENT AND RELATED PRODUCT | Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences (CN) | 2024-06-05 | — | — | EP | disclosed |
| US-11865085-B1 | Deoxycholic acid injections for snoring and obstructive sleep apnea | Schieber, Andrew (US) | 2024-01-09 | — | — | US | disclosed |
| US-20230226143-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A COMBINATION OF A GUANYLATE CYCLASE C (GUCY2C) AGONIST AND A SHORT-CHAIN FATTY ACID OR PRODRUG THEREOF | OCVIRK SOREN (DE) | 2023-07-20 | — | — | US | disclosed |
| CN-116236490-A | Application of deoxycholic acid and medicine | 四川大学 | 2023-06-09 | — | — | CN | disclosed |
| WO-2023079362-A1 | PROCESSABLE COMPOSITIONS AND USE FOR THE SAME | RIPPLE THERAPEUTICS CORPORATION (CA) | 2023-05-11 | — | — | WO | disclosed |
| US-20150094261-A1 | SYNTHETIC BILE ACID COMPOSITIONS AND METHODS | ALLERGAN SALES, LLC | 2015-04-02 | — | — | US | disclosed |
| US-8242294-B2 | Synthetic bile acid compositions and methods | KYTHERA BIOPHARMACEUTICALS, INC. (US) | 2012-08-14 | — | — | US | disclosed |
| US-20110005596-A1 | Dye for dye-sensitized solar cell and dye-sensitized solar cell including the same | SAMSUNG SDI CO., LTD. (KR) | 2011-01-13 | — | — | US | disclosed |
| US-20110005596-A1 | Dye for dye-sensitized solar cell and dye-sensitized solar cell including the same | SAMSUNG SDI CO., LTD. (KR) | 2011-01-13 | — | — | US | disclosed |
| US-20100160276-A1 | SYNTHETIC BILE ACID COMPOSITIONS AND METHODS | KYTHERA BIOPHARMACEUTICALS, INC. | 2010-06-24 | — | — | US | disclosed |
| US-20080318870-A1 | SYNTHETIC BILE ACID COMPOSITIONS AND METHODS | KYTHERA BIOPHARMACEUTICALS, INC. | 2008-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230226143-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A COMBINATION OF A GUANYLATE CYCLASE C (GUCY2C) AGONIST AND A SHORT-CHAIN FATTY ACID OR PRODRUG THEREOF | GUCY1B2, GUCY1A2, GUCY1A1 | GPBAR1 25/4885NR1H4 222/4885PDE3A 28/4885 |
| US-20150094261-A1 | SYNTHETIC BILE ACID COMPOSITIONS AND METHODS | NR1H4, CYP27A1, CYP7A1 | GPBAR1 6/4885NR1H4 1/4885PDE3A 3491/4885 |
| US-20110005596-A1 | Dye for dye-sensitized solar cell and dye-sensitized solar cell including the same | CRY1, DSG1, DACH1 | GPBAR1 1415/4885NR1H4 1493/4885PDE3A 4560/4885 |
| US-20100160276-A1 | SYNTHETIC BILE ACID COMPOSITIONS AND METHODS | NR1H4, CYP27A1, CYP7A1 | GPBAR1 6/4885NR1H4 1/4885PDE3A 3491/4885 |
| US-20080318870-A1 | SYNTHETIC BILE ACID COMPOSITIONS AND METHODS | NR1H4, CYP27A1, CYP7A1 | GPBAR1 6/4885NR1H4 1/4885PDE3A 3491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.